Clarient Diagnostic Services, an affiliate of GE Healthcare, has entered into a collaboration agreement with GlaxoSmithKline that is aimed at improving cancer patients' access to diagnostic testing.
Through the collaboration, the organizations will establish a network of clinical laboratories to identify genetic mutations associated with different tumor types.
"Our arrangement with GSK will enable us to leverage our clinical, technical and quality management expertise to credential laboratory partners worldwide," said Cindy Collins, CEO of Clarient.
The laboratory testing will initially focus on more than 70 mutations relevant to melanoma, and as the network of clinical laboratories develops, the organizations aim to expand testing beyond melanoma.
More articles on GE Healthcare:
GE Healthcare announces FDA approval of SenoClaire
5 things to know about the global HIE market
20 healthcare CEOs take on the #IceBucketChallenge